Literature DB >> 16455186

Diclofenac for treatment of nocturia caused by nocturnal polyuria: a prospective, randomised, double-blind, placebo-controlled crossover study.

Sanjai K Addla1, Adebanji B Adeyoju, Donald Neilson, Patrick O'Reilly.   

Abstract

OBJECTIVES: To investigate the efficacy of diclofenac 50 mg enteric-coated tablet (Non-Steroidal Anti-Inflammatory Drug) in the treatment of nocturnal polyuria.
MATERIALS AND METHODS: 26 patients (20 male and 6 female) with a mean age of 72 years (range 52-90) diagnosed with nocturnal polyuria were recruited. The study period comprised 2 weeks of either placebo or active medication taken at 2100 h. Following one-week rest period, patients were crossed over to the other medication for a further 2 weeks. Frequency volume charts were completed during the second week of each of the two study periods along with feedback forms to assess any subjective improvement in symptoms during each of the study periods.
RESULTS: A significant improvement in the symptoms was noted for diclofenac when compared with the placebo. The mean nocturnal frequency decreased from 2.7 to 2.3 (p<0.004) and the mean ratio of night-time to 24 h urine volume decreased from 44% to 39% (p<0.001). No significant side effects were reported.
CONCLUSIONS: NSAIDs are effective in the treatment of nocturnal polyuria causing a decrease in nocturnal frequency with subjective symptom improvement. Our study suggests a novel treatment option for this common condition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16455186     DOI: 10.1016/j.eururo.2005.11.026

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  8 in total

1.  Liquid chromatography-mass spectrometry identification of serum biomarkers for nocturia in aged men.

Authors:  Satoru Kira; Takahiko Mitsui; Tatsuya Miyamoto; Tatsuya Ihara; Hiroshi Nakagomi; Yuka Hashimoto; Hajime Takamatsu; Masayuki Tanahashi; Masahiro Takeda; Norifumi Sawada; Karl-Erik Andersson; Masayuki Takeda
Journal:  World J Urol       Date:  2019-01-23       Impact factor: 4.226

2.  The impact of adding low-dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia.

Authors:  Abul-Fotouh Ahmed; Aref Maarouf; Essam Shalaby; Ahmad H Gabr; Ashraf Shahin; Ammar Ghobish
Journal:  World J Urol       Date:  2014-08-20       Impact factor: 4.226

Review 3.  Nocturia: aetiology and treatment in adults.

Authors:  Hasan Dani; Ashanda Esdaille; Jeffrey P Weiss
Journal:  Nat Rev Urol       Date:  2016-07-26       Impact factor: 14.432

Review 4.  Combination therapies for the management of nocturia and its comorbidities.

Authors:  Cenk Murat Yazici; Omer Kurt
Journal:  Res Rep Urol       Date:  2015-04-20

Review 5.  Pharmacotherapy for Nocturia.

Authors:  Karl-Erik Andersson; Philip Van Kerrebroeck
Journal:  Curr Urol Rep       Date:  2018-02-09       Impact factor: 3.092

6.  Detection of Prostatic Inflammation From Peripheral Lymphocyte Count and Free/Total PSA Ratio in Men With LUTS/BPH.

Authors:  Xinyang Liao; Zhuang Tang; Jianzhong Ai; Hang Xu; Shiyu Zhang; Liangren Liu; Shi Qiu; Ping Tan; Yu Fan; Lu Yang; Qiang Wei
Journal:  Front Pharmacol       Date:  2020-04-30       Impact factor: 5.810

7.  A systematic evaluation of factors associated with nocturia--the population-based FINNO study.

Authors:  Kari A O Tikkinen; Anssi Auvinen; Theodore M Johnson; Jeffrey P Weiss; Tapani Keränen; Aila Tiitinen; Olli Polo; Markku Partinen; Teuvo L J Tammela
Journal:  Am J Epidemiol       Date:  2009-06-10       Impact factor: 4.897

8.  Lipidosterolic extract of serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells.

Authors:  Nanor Sirab; Grégoire Robert; Virginie Fasolo; Aurélien Descazeaud; Francis Vacherot; Alexandre de la Taille; Stéphane Terry
Journal:  Int J Mol Sci       Date:  2013-07-10       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.